BACKGROUND Aspirin is of moderate overall benefit for patients with acute disabling ischemic stroke. It is unclear whether functional outcome could be improved after stroke by targeting aspirin to patients with a high risk of recurrent thrombosis or a low risk of haemorrhage. AIMS We aimed to determine whether patients at higher risk of thrombotic events or poor functional outcome, or lower r...

Studies investigating the association between interleukin-6 (IL-6) gene-174 G/C polymorphism (rs1800795) and thrombosis disorder risk reported conflicting results. The aim of our study was to assess the association between the IL-6 gene 174 G/C polymorphisms and the risk of thrombosis disorders.Thirty four case-control studies in 29 articles with 29,865 individuals were incorporated in this met...

Several lines of evidence garnered so far attest that coronavirus disease 2019 (COVID-19) is associated with a remarkably high rate thrombotic events.[1] Di Minno et al recently published the results critical literature review and meta-analysis, including 20 studies totaling 1988 COVID-19 patients,[2] which revealed weighted mean prevalence venous thromboembolism (VTE), deep vein thrombosis (DV...

A cute arterial thrombosis can cause myocardial infarction (MI), ischemic stroke, and acute limb ischemia (ALI). The annual incidences of such events are high; there were 935,000 MI and 795,000 stroke events in the United States in 2008.1 However, the incidence and prevalence of acute peripheral arterial thrombosis is not well described, even in lieu of its devastating consequences, including m...

Introduction Thrombotic microangiopathy (TMA) describes a pathological process of microvascular thrombosis, consumptive thrombocytopenia and microangiopathic haemolytic anaemia, leading to end-organ ischaemia and infarction. TMA is a feature of a number of clinical disorders, most commonly hemolytic uremic syndrome (HUS) and thrombotic thrombocytopaenic purpura. Several molecular mechanisms med...

We report on a patient with systemic lupus erythematosus, who, during the course of the illness, developed thrombotic thrombocytopenic purpura. In this case, the coexistence of these two conditions was confirmed by laboratory and pathologic findings. The infusion of fresh frozen plasma with plasmapheresis reversed the course of thrombotic thrombocytopenic purpura.

In patients presenting with thrombotic thrombocytopenia purpura and non-ST elevation myocardial infarction, prompt initiation of plasma exchange takes precedence over other invasive diagnostic procedures for coronary artery disease. Such procedures should be delayed until clinical condition and laboratory parameters have been stabilized.

the invention of the drug-eluting stent (des) has brought about revolutionary changes in the field of interventional cardiology. in the des era, in-stent restenosis has declined but new issues such as stent thrombosis have emerged. one of the emerging paradigms in the des era is stent fracture. there are reports about stent fracture leading to in-stent restenosis or stent thrombosis. most of th...

PURPOSE OF REVIEW This review focuses on recent advances in the use of immune-based therapy to treat patients with refractory and relapsing acquired thrombotic thrombocytopenic purpura. RECENT FINDINGS Advances in understanding of the pathophysiology of idiopathic thrombotic thrombocytopenic purpura have provided the rationale for immune-based treatment approaches to refractory and relapsing ...